Drugs / Lipovirtide
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05349968 | Jun 2022 → Jun 2023 | HIV infectious disease | Shanxi Kangbao Biological Product Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04592315 | Jan 2021 → May 2023 | HIV infectious disease | Shanxi Kangbao Biological Product Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06061536 | Nov 2023 → Nov 2024 | HIV infectious disease | Shanxi Kangbao Biological Product Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lipovirtide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04592315 ↗ |
| Known as | Lipovirtide Injection | “Single dosage of Lipovirtide Injection” NCT04592315 ↗ |
| Route | Subcutaneous | “Injected subcutaneously at room temperature into the abdomen” NCT05349968 ↗ |